Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Emergent Biosolutions
(NY:
EBS
)
8.960
+0.190 (+2.17%)
Official Closing Price
Updated: 4:10 PM EST, Nov 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Emergent Biosolutions
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
What's Going On With Emergent BioSolutions Stock Wednesday?
October 02, 2024
Emergent BioSolutions stock is trading higher after the company announced the closing of a $100 million asset-backed revolving loan facility.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
September 26, 2024
Via
Benzinga
Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines
September 25, 2024
Emergent BioSolutions secures $400M in orders for smallpox and mpox products, receives FDA approval for ACAM2000's expanded use, and updates its 2024 revenue forecast while beating Q2 sales estimates.
Via
Benzinga
Exposures
Product Safety
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 02, 2024
Via
Benzinga
(EBS) - Analyzing Emergent BioSolutions's Short Interest
August 20, 2024
Via
Benzinga
7 Analysts Assess Emergent BioSolutions: What You Need To Know
August 16, 2024
Via
Benzinga
Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine
August 30, 2024
Emergent BioSolutions stock jumped early Friday.
Via
Investor's Business Daily
Exposures
Product Safety
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
August 30, 2024
The FDA has approved Emergent BioSolutions' supplemental Biologics License Application for ACAM2000 to include the prevention of mpox disease in high-risk individuals, with the approval based on human...
Via
Benzinga
Exposures
Product Safety
Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
August 30, 2024
Via
Benzinga
WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'
August 26, 2024
To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan.
Via
Benzinga
Macy's Reports Weak Sales, Joins JD.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 21, 2024
Via
Benzinga
3 Promising Vaccine Stocks To Watch In The Event Of A Mpox Surge
August 19, 2024
Mpox rerun is making these stocks soar. But a non-vaccine approach could yield greater gains.
Via
Talk Markets
Why Emergent BioSolutions Stock Is Skyrocketing Today
August 16, 2024
Concerns about the mpox outbreak are causing Emergent BioSolutions' shares to jump.
Via
The Motley Fool
H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday
August 16, 2024
Via
Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
August 16, 2024
Via
Benzinga
Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On?
August 15, 2024
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa.
Via
Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
August 15, 2024
Via
Benzinga
WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak
August 14, 2024
A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fighting the virus.
Via
Benzinga
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
August 07, 2024
Emergent BioSolutions reported Q2 2024 sales of $254.7 million, beating estimates but showing a 25% decline year-over-year. Despite a significant adjusted EPS loss and mixed performance across product...
Via
Benzinga
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 07, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 07, 2024
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!
Via
InvestorPlace
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
August 07, 2024
Via
Benzinga
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
August 07, 2024
EBS earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
August 01, 2024
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%.
Via
Benzinga
How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings
July 18, 2024
American Express offers an annual dividend yield of 1.12%, or $2.80 a year. How can investors pocket a regular $500 monthly?
Via
Benzinga
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
July 16, 2024
JNJ to release 2Q financial results on July 17. Expected earnings $2.70/share, revenue $22.29B. Investors eye 3.32% dividend yield for gains.
Via
Benzinga
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
July 09, 2024
Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71.
Via
Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
July 09, 2024
Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration.
Via
Benzinga
Exposures
COVID-19
Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?
July 02, 2024
Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health and Human Services. The funding ensures the supply of critical medical...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.